Cardiac surgery with cardiopulmonary bypass triggers an acute inflammatory response in the lungs. This response gives rise to fibrin deposition in the microvasculature and alveoli of the lungs. Fibrin deposition in the microvasculature increases alveolar dead space, while fibrin deposition in alveoli causes shunting. We investigated whether prophylactic nebulised heparin could limit this form of lung injury. We undertook a single-centre double-blind randomised trial. Forty patients undergoing elective cardiac surgery with cardiopulmonary bypass were randomised to prophylactic nebulised heparin (50,000 U) or placebo. The primary endpoint was the change in arterial oxygen levels over the operative period. Secondary endpoints included endtidal CO 2 , the alveolar dead space fraction and bleeding complications. We found nebulised heparin did not improve arterial oxygen levels. Nebulised heparin was, however, associated with a lower alveolar dead space fraction (P <0.05) and lower tidal volumes at the end of surgery (P <0.01). Nebulised heparin was not associated with bleeding complications. In conclusion, prophylactic nebulised heparin did not improve oxygenation, but was associated with evidence of better alveolar perfusion and CO 2 elimination at the end of surgery.
Approximately 800,000 patients undergo cardiac surgery each year 1 . Cardiac surgery with cardiopulmonary bypass (CPB) precipitates an acute inflammatory response, causing lung injury which may result in postoperative complications including prolonged mechanical ventilation, long-term disability and death [2] [3] [4] [5] [6] [7] .
Triggers of lung inflammation include ischaemia (as the lungs are not ventilated or perfused during CPB), contact of blood with the foreign surfaces of the CPB circuit, and surgical trauma 4, 6 . A recent randomised multicentre study found limiting the acute inflammatory response with dexamethasone reduced the incidence of respiratory failure, the duration of mechanical ventilation, and the length of both intensive care and hospital stays 3 .
One mechanism by which acute inflammation causes lung injury is the deposition of fibrin in the microvasculature and alveoli [7] [8] [9] [10] [11] . Histological studies have demonstrated deposition of thrombi in pulmonary capillaries, venules, and arterioles following cardiac surgery 12 . Furthermore, interventional studies found that administration of an intravenous heparin infusion reduced the extent of microvascular thrombi and preserved the alveolar dead space 9, 10 . Nebulisation delivers heparin not only to the microvasculature of the lungs, but also to the alveoli, and this mode of administration may therefore maximise the actions of heparin on the lungs while minimising systemic effects on coagulation 13 . Nebulised heparin may have other beneficial effects on the lungs, including the release of nitric oxide from the microvasculature, which may improve alveolar perfusion, and in addition, heparin is a bronchodilator [14] [15] [16] [17] . Nebulised heparin was found to be of benefit in other forms of acute lung injury. A study of critically ill patients with, or at risk of, the acute respiratory distress syndrome found nebulised heparin reduced the duration of mechanical ventilation 18 . Thus, we undertook this pilot study to investigate whether prophylactic nebulised heparin improved oxygenation following cardiac surgery.
Materials and methods

Study design and participants
The study was undertaken at Barwon Hospital, a 406bed general medical and surgical teaching hospital. The study design was a pilot double-blind randomised trial of nebulised heparin in 40 patients undergoing elective cardiac surgery with CPB. Inclusion criteria consisted of age of at least 18 years and proposed surgery likely to require a prolonged period of CPB. Eligible operations included four or more coronary artery bypass grafts or a combined procedure that included at least two of the following: coronary artery bypass grafts, valve replacement, or other cardiac surgical procedure. Exclusion criteria included heparin allergy, a history of heparin-induced thrombocytopenia, creatinine >130 µmol/l, preoperative administration of heparin or systemic immunosuppressants (such as steroids, cyclosporin, azathioprine), or marked limitation of physical activity (defined as development of fatigue or shortness of breath on walking 100 metres). The study was approved by the Barwon Health Human Research Ethics Committee (13/41) for a period of four years. All patients gave written informed consent before participation. The trial was registered with the Australian New Zealand Clinical Trials Registry: ACTRN12613000738729. The submission to the registry was undertaken two months before the first patient enrolment. The registration date was, however, delayed due to an oversight by the authors in acknowledgement of a query by the Registry. The authors confirm that all related trials for this intervention are registered.
Intervention
Patients were given a single nebulised 10 ml dose of heparin (50,000 U) (Pfizer Australia Pty Ltd, West Ryde, New South Wales) or 10 ml of 0.9% sodium chloride (Pfizer). The study drug was administered immediately following intubation. The Aeroneb® Solo (Aerogen Ltd, Galway, Ireland) single-use, vibrating mesh nebuliser was used. The nebuliser was placed in the inspiratory limb of the ventilator circuit and an expiratory filter was placed in the circuit. The dose of heparin was based on previous studies which found 125,000 U six-hourly was safe and beneficial in established lung injury 13, 18, 19 . A lower dose was used for the current study as treatment was given to prevent rather than treat lung injury.
Randomisation and allocation concealment
The hospital's research pharmacist used a computergenerated randomisation sequence that allocated 20 patients to placebo and 20 to heparin. Randomisation was blocked to ensure that after every fourth patient enrolled, equal numbers had been allocated to the two groups. The study medication ampoules were identical.
Surgery
All patients were administered tranexamic acid intravenously following anaesthetic induction. Patients were administered approximately 600 IU/kg intravenous heparin to achieve a target-activated clotting time of >480 seconds. Central cannulation was used. CPB consisted of a Quadrox hollow-fibre oxygenator with integrated 40 µm arterial filter (Maquet Cardiopulmonary, Rastatt, Germany), open hard-shell venous reservoir (Maquet Cardiopulmonary) and P.h.i.s.i.o.-coated biocompatible tubing (Sorin, Milan, Italy). The heart-lung machine consisted of a Stockert S5 HLM (Stockert, Germany) utilising a mast-mounted arterial pump which had occlusion set using the dynamic occlusion method. The system was primed with 800 ml Plasma-Lyte® 148 (Baxter Healthcare, Deerfield, IL, USA), 100 ml 20% Albumex® (CSL, Melbourne, Victoria), 50 ml 8.4% sodium bicarbonate (Baxter Healthcare) and 10,000 IU heparin (Pfizer). Patients were cooled to 34°C after initiating CPB. Non-pulsatile arterial flow was maintained at a cardiac index >2.4 l/min/m 2 , mean arterial pressure >50 mmHg and arterial blood gases within normal limits. Packed cell transfusion was given if the haematocrit was less than 18. Patients were rewarmed to >36.5°C. Protamine was administered after discontinuation of CPB (1 mg of protamine per 100 U of intravenous heparin). Following decannulation, the heparinised blood was returned to the patient. Due to the complexity of cardiac surgery, and with the additional challenge of undertaking a novel intervention, the intraoperative management was pragmatic, and mechanical ventilation was therefore managed by anaesthetic staff according to their usual practice. Patients were typically ventilated in a volume-controlled mode, with initial tidal volumes of approximately 6 to 7 ml/kg, rate of 10 to 12 breaths per minute, and minute ventilation adjusted on the basis of arterial CO 2 levels.
Data collection
The primary outcome was the change in the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO 2 /FiO 2 ) ratio from baseline to the end of surgery. Secondary outcomes included the alveolar dead space fraction-calculated as (PaCO 2 -end-tidal CO 2 )/PaCO 2 , the respiratory rate, tidal volume, peak inspiratory pressure, positive end-expiratory pressure, minute ventilation, heart rate, blood pressure, pulmonary artery pressure and cardiac output. These variables were measured at the following timepoints: preoperatively-approximately 20 minutes after intubation and commencement of nebulisation, postoperatively-after discontinuation of CPB and protamine administration, during the first hour in the ICU and between two and four hours after arrival in the ICU. Blood product usage and evidence of lung bleeding (as evidenced by frank blood on lung suctioning) were documented throughout the operative period and over the first 12 hours in the ICU. Safety outcomes including duration of hospital stay and mortality were documented.
Statistical analysis
Continuous variables were reported as mean ± SD or median and (IQR), where appropriate, and compared using Student's t-test, or Wilcoxon rank sum test, respectively. Categorical variables were compared using chi-square tests or Fisher's exact tests. All reported P-values are two-sided. Based on the results of an earlier study, we expected the fall in the PaO 2 /FiO 2 over the operative period in the nebulised heparin arm to be 110 lower than that of the placebo arm 12 . The SD was expected to be 100. Based on these assumptions, for power of 0.9 and alpha of 0.05, 40 patients were required. An exploratory analysis was undertaken of secondary endpoints. A P-value of 0.05 or less was considered to indicate statistical significance. Analyses were conducted with Stata version 13 (StataCorp, College Station, TX, USA).
Results
Enrolment data
Between June 2013 and May 2014, 20 patients were randomised to nebulised heparin and 20 to placebo. All patients received the allocated treatment and were included in the final analysis ( Figure 1 ). The characteristics of the two groups were similar. In particular, there were no differences in the EuroSCORE, history of smoking, or chronic pulmonary disease (Table1).
Outcomes
The primary endpoint of change in the PaO 2 /FiO 2 over the operative period was similar in the two groups (-131 ± 138 versus -72 ± 141, P=0.2, Figure 1 ). The alveolar dead space fraction was lower (0.11 ± 0.07 versus 0.16 ± 0.08, P <0.05), tidal volume was lower (7.9 ± 1.3 versus 9.0 ± 1.1 ml/kg of ideal body weight, P <0.01) and end-tidal CO 2 was higher (35.3 ± 3.3 versus 32.9 ± 2.4 mmHg, P <0.05), in the heparin group at the end of surgery ( Figure 2) .
The respiratory rate, arterial partial pressure of carbon dioxide (PaCO 2 ), and haemodynamic variables were similar in the two groups throughout the study. Long-term outcomes, including hours of mechanical ventilation, length of intensive care and hospital stays, return to the operating theatre, hospital re-admission at 30 days and death at 30 days were also similar between the two groups ( Table 2 ). Blood product use, fluid balance, and coagulation parameters were also similar between groups (Table 3) . One patient in each group had frank blood in the airway on suctioning. In the heparin group, the bleeding was thought to be related to a lung laceration sustained during surgery. In the placebo group it was thought to be related to a difficult intubation.
Discussion
In this double-blind randomised study of patients undergoing elective cardiac surgery with CPB, nebulised heparin did not improve arterial oxygen levels at the end of surgery, but was associated with improvements in secondary outcomes including a lower alveolar dead space fraction and lower tidal volumes at the end of surgery. These findings are consistent with better alveolar perfusion with more efficient CO 2 elimination by the lungs. Nebulised heparin was not associated with bleeding complications and had no impact on systemic markers of coagulation.
Nebulised heparin has the potential to improve alveolar perfusion through a number of mechanisms. Previous studies have demonstrated that a preoperative intravenous heparin infusion reduced the extent of microvascular lung thrombi and preserved the alveolar dead space in patients undergoing cardiac surgery 9, 10 . Heparin has immediate anticoagulant effects through increased antithrombin activity but also delayed anticoagulant effects (mediated by protein synthesis) including endothelial expression of heparan sulfate, endothelial and platelet secretion of tissuefactor pathway inhibitor and inhibition of endothelial and monocyte expression of tissue factor [20] [21] [22] . Heparin also has fibrinolytic properties through the release of tissue plasminogen activator from the endothelium 10 . In addition, heparin triggers the release of nitric oxide from the microvasculature, which acts as a local vasodilator and may therefore also improve alveolar perfusion 14, 15 .
Despite evidence of better alveolar perfusion, nebulised heparin did not improve the PaO 2 /FiO 2 at the end of surgery, which was the primary endpoint of the study. Paradoxically, it is possible that better alveolar perfusion at the end of surgery could lead to a deterioration in oxygenation, if perfusion were maintained to dependent, atelectatic areas of the lungs. In addition, the lower tidal volumes used in the heparin group at the end of surgery could also reduce arterial oxygen levels 23 .
The lower alveolar dead space fraction and tidal volumes did not persist during the first four hours in the ICU. This finding may reflect metabolism by heparinases and sequestration of heparin by endothelial cells in the lungs, limiting the duration of the action 24, 25 . It is plausible that further doses of nebulised heparin in the ICU may have prolonged its actions and resulted in greater clinical benefits. These findings support larger clinical studies of nebulised heparin to assess if continued administration through the postoperative period might have greater clinical benefit.
Limitations
Cardiac surgery is complex. Patients are often elderly and have a range of comorbidities. In small studies such as this, even marginal differences in the extent of comorbidites, such as chronic lung disease and history of smoking, or the extent of operative complications between groups, could markedly influence postoperative outcomes. Enrolment criteria that defined a more homogeneous group could have minimised such variations in postoperative outcomes.
The ventilation management was pragmatic and not protocolised, thus introducing the possibility of variation in practices between groups. We found arterial CO 2 levels and respiratory rates were, however, the same in both groups throughout the study, suggesting that practices were similar. This pragmatic approach was chosen to minimise the complexity of a challenging study. Nebulised heparin had not previously been administered to patients undergoing cardiac surgery and clinicians were apprehensive as to the risk of potential complications.
Conclusion
Prophylactic nebulised heparin did not improve oxygenation, but was associated with reductions in the alveolar dead space fraction and tidal volumes at the end of cardiac surgery. These findings are consistent with better CO 2 elimination through improved alveolar perfusion. 
P-value
Mechanical ventilation, hrs 13.5 (7-38) 15 (7-26) 0.7
Intensive care stay, days 2 (1-3.5) 2 (1-3) 0.9
Hospital stay, days 6 (5-9) 7 (6-10) 0.4
Return to operating theatre, % 10 0 0.1
Hospital readmit at 30 days, % 10 0 0.1
Death at 30 days, % 5 0 0.3
Median and IQR and percentage are shown. Blood product administration was recorded in theatre and over the first 12 hours in the ICU. Fluid balance and chest tube drainage was only recorded over the first 12 hours in ICU. FFP=fresh frozen plasma, Max ACT=maximum activated clotting time measured during cardiopulmonary bypass, aPTT=activated partial thromboplastin time. Mean and SD, percentage or median (IQR) are shown.
